scholarly journals Intraocular therapy in noninfectious uveitis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Rocco Luigi Modugno ◽  
Ilaria Testi ◽  
Carlos Pavesio
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Treatment Options ◽  
Local Treatment ◽  
Local Therapy ◽  
Systemic Administration ◽  
Vascular Endothelial ◽  
Systemic Corticosteroids ◽  
Infectious Uveitis ◽  
Endothelial Growth Factor

AbstractSystemic corticosteroids and immunosuppressant agents are the mainstay of therapy for non-infectious uveitis (NIU). However, the risks associated with systemic administration and the need of delivering an effective and safe anti-inflammatory treatment targeted to the site of inflammation have prompt the use of local therapy in the management of NIU. This review will analyse the different local treatment options available, including corticosteroids, anti-vascular endothelial growth factor (VEGF), methotrexate and the recent biologics.

scholarly journals Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor

1995 ◽  
Vol 21 (2) ◽  
pp. 314-325 ◽  
Author(s):  
Christophe Bauters ◽  
Takayuki Asahara ◽  
Lu P. Zheng ◽  
Satoshi Takeshita ◽  
Stuart Bunting ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Therapeutic Angiogenesis ◽  
Systemic Administration ◽  
Vascular Endothelial ◽  
Site Specific ◽  
Endothelial Growth Factor

Anti–vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularisation

2013 ◽  
Vol 07 (02) ◽  
pp. 84
Author(s):  
Josep Badal ◽  
Luis Amselem ◽  
Ricardo Aleman ◽  
Frederic Huste ◽  
◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Treatment Options ◽  
Young Patients ◽  
Choroidal Neovascularisation ◽  
Vascular Endothelial ◽  
Pathological Myopia ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

Pathological myopia represents the most common cause of choroidal neovascularisation in young patients. Its natural course has a devastating prognosis. Several treatments have been assessed, but photodynamic therapy is currently the only approved treatment for subfoveal choroidal neovascularisation related to pathological myopia. Anti-vascular endothelial growth factor therapy has demonstrated promising results in any form and localisation of choroidal neovascularisation, although there is an absence of data obtained from randomised clinical trials. The aim of this article is to compare different treatment options, combinations and retreatment criteria for the management of choroidal neovascularisation in eyes with high myopia.

scholarly journals Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Afshin Amini ◽  
Samar Masoumi Moghaddam ◽  
David L. Morris ◽  
Mohammad H. Pourgholami
Keyword(s):  
Ovarian Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Treatment Options ◽  
Malignant Ascites ◽  
Vascular Endothelial ◽  
Chemotherapeutic Drugs ◽  
Gynecologic Malignancy ◽  
Preclinical And Clinical Studies ◽  
Endothelial Growth Factor

Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis, agents rendering VEGF ineffective by neutralizing VEGF (bevacizumab), blocking its receptors (aflibercept), or interfering with the postreceptor signaling pathways (sunitinib) provide us with the rational treatment options. These agents are generally used in combination with the standard chemotherapeutic drugs. Here, we discuss the basis of and the logic behind the use of these agents in the treatment of epithelial ovarian cancer, as well as their evaluation in different preclinical and clinical studies.

scholarly journals Local delivery of hydrogel encapsulated vascular endothelial growth factor for the prevention of medication-related osteonecrosis of the jaw

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Dileep Sharma ◽  
Stephen Hamlet ◽  
Cedryck Vaquette ◽  
Eugen Bogdan Petcu ◽  
Poornima Ramamurthy ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Treatment Options ◽  
Systemic Effect ◽  
Osteonecrosis Of The Jaw ◽  
Local Delivery ◽  
Vascular Endothelial ◽  
Cytokine Levels ◽  
Defect Area ◽  
Endothelial Growth Factor

AbstractThe anti-angiogenic effects of bisphosphonates have been hypothesized as one of the major etiologic factors in the development of medication-related osteonecrosis of the jaw (MRONJ), a severe debilitating condition with limited treatment options. This study evaluated the potential of a gelatine-hyaluronic acid hydrogel loaded with the angiogenic growth factor, vascular endothelial growth factor (VEGF), as a local delivery system to aid in maintaining vascularization in a bisphosphonate-treated (Zoledronic Acid) rodent maxillary extraction defect. Healing was assessed four weeks after implantation of the VEGF-hydrogel into extraction sockets. Gross examination and histological assessment showed that total osteonecrosis and inflammatory infiltrate was significantly reduced in the presence of VEGF. Also, total vascularity and specifically neovascularization, was significantly improved in animals that received VEGF hydrogel. Gene expression of vascular, inflammatory and bone specific markers within the defect area were also significantly altered in the presence of VEGF. Furthermore, plasma cytokine levels were assessed to determine the systemic effect of locally delivered VEGF and showed similar outcomes. In conclusion, the use of locally delivered VEGF within healing extraction sockets assists bone healing and prevents MRONJ via a pro-angiogenic and immunomodulatory mechanism.

Local Treatment of Meniscal Lesions with Vascular Endothelial Growth Factor

2010 ◽  
Vol 92 (16) ◽  
pp. 2682-2691 ◽  
Author(s):  
Sebastian Kopf ◽  
Falk Birkenfeld ◽  
Roland Becker ◽  
Wolf Petersen ◽  
Christian Stärke ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Local Treatment ◽  
Vascular Endothelial ◽  
Meniscal Lesions ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document